Yikai Zhang

Yikai Zhang

Auto-generated profile, based on publicly available information

Yikai Zhang

Department of Endocrinology and Metabolism, The Second Affiliated Hospital, Zhejiang University School of Medicine, 310009 Hangzhou, Zhejiang, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

24 March 2025 in Advanced Science
Verified
Journal Article
Open access
YZYikai Zhang
Yikai Zhang
YXYi Xie
Yi Xie
SXShenglong Xia
Shenglong Xia
XGXinnuo Ge
Xinnuo Ge
JLJiaying Li
Jiaying Li
CZChao Zheng
Chao Zheng
Colorectal cancer (CRC) is a leading cause of cancer mortality while diabetes is a recognized risk factor for CRC. Here we report that tirzepatide (TZP), a novel polypeptide/glucagon‐like peptide 1 receptor (GIPR/GLP‐1R) agonist for the treatment of diabetes, has a role in attenuating CRC growth. TZP significantly inhibited colon cancer cell proliferation promoted apoptosis in vitro and induced durable tumor regression in vivo under hyperglycemic and nonhyperglycemic conditions across multiple murine cancer models. As glucose metabolism is known to critically regulate colon cancer progression, spatial metabolomics results revealed that glucose metabolites are robustly reduced in the colon cancer regions of the TZP‐treated mice. TZP inhibited glucose uptake and destabilized hypoxia‐inducible factor‐1 alpha (HIF‐1α) with reduced expression and activity of the rate‐limiting enzymes 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase 3 (PFKFB3) and phosphofructokinase 1 (PFK‐1). These effects contributed to the downregulation of glycolysis and the tricarboxylic acid (TCA) cycle. TZP also delayed tumor development in a patient‐derived xenograft (PDX) mouse model accompanied by HIF‐1α mediated PFKFB3‐PFK‐1 inhibition. Therefore, the study provides strong evidence that glycolysis‐blocking TZP, besides its application in treating type 2 diabetes, has the potential for preclinical studies as a therapy for colorectal cancer used either as monotherapy or in combination with other anticancer therapies.

1 June 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
YZYikai Zhang
Yikai Zhang
SWShengyao Wang
Shengyao Wang
QZQiao Zhou
Qiao Zhou
YXYi Xie
Yi Xie
YHYepeng Hu
Yepeng Hu
CZChao Zheng
Chao Zheng
BACKGROUND: Restoring the capacity of endothelial progenitor cells (EPCs) to promote angiogenesis is the major therapeutic strategy of diabetic peripheral artery disease. The aim of this study was to investigate the effects of GLP-1 (glucagon-like peptide 1; 32–36)—an end product of GLP-1—on angiogenesis of EPCs and T1DM (type 1 diabetes) mice, as well as its interaction with the classical GLP-1R (GLP-1 receptor) pathway and its effect on mitochondrial metabolism. METHODS: In in vivo experiments, we conducted streptozocin-induced type 1 diabetic mice as a murine model of unilateral hind limb ischemia to examine the therapeutic potential of GLP-1(32–36) on angiogenesis. We also generated Glp1r −/− mice to detect whether GLP-1R is required for angiogenic function of GLP-1(32–36). In in vitro experiments, EPCs isolated from the mouse bone marrow and human umbilical cord blood samples were used to detect GLP-1(32–36)–mediated angiogenic capability under high glucose treatment. RESULTS: We demonstrated that GLP-1(32–36) did not affect insulin secretion but could significantly rescue angiogenic function and blood perfusion in ischemic limb of streptozocin-induced T1DM mice, a function similar to its parental GLP-1. We also found that GLP-1(32–36) promotes angiogenesis in EPCs exposed to high glucose. Specifically, GLP-1(32–36) has a causal role in improving fragile mitochondrial function and metabolism via the GLP-1R–mediated pathway. We further demonstrated that GLP-1(32–36) rescued diabetic ischemic lower limbs by activating the GLP-1R–dependent eNOS (endothelial NO synthase)/cGMP/PKG (protein kinase G) pathway. CONCLUSIONS: Our study provides a novel mechanism with which GLP-1(32–36) acts in modulating metabolic reprogramming toward glycolytic flux in partnership with GLP-1R for improved angiogenesis in high glucose–exposed EPCs and T1DM murine models. We propose that GLP-1(32–36) could be used as a monotherapy or add-on therapy with existing treatments for peripheral artery disease. REGISTRATION: URL: www.ebi.ac.uk/metabolights/ ; Unique identifier: MTBLS9543.

20 October 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MWMingming Wang
Mingming Wang
MCMinchun Chen
Minchun Chen
YDYi Ding
Yi Ding
ZZZhihui Zhu
Zhihui Zhu
YZYikai Zhang
Yikai Zhang
AWAidong Wen
Aidong Wen
Vascular endothelial cells play an important role in modulating anti-thrombus and maintaining the natural function of vascular by secreting many active substances. β-boswellic acid (β-BA) is an active triterpenoid compound from the extract of boswellia serrate. In this study, it is demonstrated that β-BA ameliorates plasma coagulation parameters, protects endothelium from blood stasis induced injury and prevents blood stasis induced impairment of endothelium-dependent vasodilatation. Moreover, it is found that β-BA significantly increases nitric oxide (NO) and cyclic guanosine 3’, 5’-monophosphate (cGMP) levels in carotid aortas of blood stasis rats. To stimulate blood stasis-like conditionsin vitro, human umbilical vein endothelial cells (HUVECs) were exposed to transient oxygen and glucose deprivation (OGD). Treatment of β-BA significantly increased intracellular NO level. Western blot and immunofluorescence as well as immunohistochemistry reveal that β-BA increases phosphorylation of enzyme nitric oxide synthase (eNOS) at Ser1177. In addition, β-BA mediated endothelium-dependent vasodilatation can be markedly blocked by eNOS inhibitor L-NAME in blood stasis rats. In OGD treated HUEVCs, the protective effect of β-BA is attenuated by knockdown of eNOS. In conclusion, the above findings provide convincing evidence for the protective effects of β-BA on blood stasis induced endothelial dysfunction by eNOS signaling pathway.

22 September 2026 in British Journal of Hospital Medicine
Verified
Journal Article
Open access
PDF file
JPJie Pan
Jie Pan
CGChengnan Guo
Chengnan Guo
QHQiuwei Huang
Qiuwei Huang
YZYikai Zhang
Yikai Zhang
YSYimin Shen
Yimin Shen
CGCaiyun Guo
Caiyun Guo
Diabetic lower extremity peripheral artery disease (PAD) is a complex and multifactorial complication of diabetes mellitus, characterized by extensive distal disease burden, accelerated progression, and a markedly elevated risk of major adverse limb events. Despite considerable advances in endovascular and surgical revascularization, limb salvage rates in this population remain suboptimal, largely due to the limited efficacy of current pharmacological options in improving microvascular perfusion, accelerating wound healing, or preventing re-occlusion. In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a transformative therapeutic class, demonstrating cardiovascular protective effects beyond glycemic control. Large-scale real-world studies have generated encouraging signals regarding their potential to reduce amputation risk and promote wound healing. However, the current evidence base remains limited, and the precise molecular mechanisms by which GLP-1 RAs may protect the diabetic lower extremity require further elucidation. This review systematically examines the epidemiology and pathophysiology of diabetic lower extremity PAD, elucidates the molecular mechanisms of GLP-1 RA-mediated vascular protection, critically evaluates clinical and real-world evidence, and discusses key challenges and future directions for optimizing therapeutic outcomes in this high risk population.